Eduardo L Franco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4506958/publications.pdf

Version: 2024-02-01

435 papers 24,686 citations

76 h-index 9553 142 g-index

457 all docs

457 docs citations

times ranked

457

16695 citing authors

#	Article	IF	CITATIONS
1	Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, The, 2004, 364, 1757-1765.	6.3	1,435
2	Sustained efficacy up to $4\hat{A}\cdot5$ years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, The, 2006, 367, 1247-1255.	6.3	1,395
3	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Ca-A Cancer Journal for Clinicians, 2012, 62, 147-172.	157.7	1,022
4	Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. New England Journal of Medicine, 2007, 357, 1579-1588.	13.9	930
5	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. American Journal of Clinical Pathology, 2012, 137, 516-542.	0.4	686
6	Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. International Journal of Cancer, 2009, 124, 516-520.	2.3	557
7	Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine. Journal of the National Cancer Institute, 2004, 96, 604-615.	3.0	482
8	The epidemiology of genital human papillomavirus infection. Vaccine, 2006, 24, S4-S15.	1.7	383
9	Chapter 6: Epidemiology and transmission dynamics of genital HPV infection. Vaccine, 2006, 24, S52-S61.	1.7	364
10	Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2012, 12, 781-789.	4.6	343
11	Risk factors for oral cancer in Brazil: A case-control study. International Journal of Cancer, 1989, 43, 992-1000.	2.3	337
12	American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the Prevention and Early Detection of Cervical Cancer. Journal of Lower Genital Tract Disease, 2012, 16, 175-204.	0.9	310
13	Human Papillomavirus Infections with Multiple Types and Risk of Cervical Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1274-1280.	1.1	280
14	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, H1-H31.	1.7	272
15	Human Papillomavirus Infection and Time to Progression and Regression of Cervical Intraepithelial Neoplasia. Journal of the National Cancer Institute, 2003, 95, 1336-1343.	3.0	269
16	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, 11-131.	1.7	261
17	Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. Journal of General Virology, 2000, 81, 2959-2968.	1.3	256
18	Dry self-sampling versus provider-sampling of cervicovaginal specimens for human papillomavirus detection in the Inuit population of Nunavik, Quebec. Journal of Medical Screening, 2012, 19, 42-48.	1.1	254

#	Article	IF	CITATIONS
19	Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecologic Oncology, 2007, 105, 530-535.	0.6	240
20	Process of care failures in invasive cervical cancer: Systematic review and meta-analysis. Preventive Medicine, 2007, 45, 93-106.	1.6	224
21	A prospective epidemiological study of gastrointestinal health effects due to the consumption of drinking water. International Journal of Environmental Health Research, 1997, 7, 5-31.	1.3	211
22	Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Preventive Medicine, 2011, 53, S12-S21.	1.6	201
23	Diagnosis delays in childhood cancer. Cancer, 2007, 110, 703-713.	2.0	198
24	Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncology, The, 2002, 3, 11-16.	5.1	196
25	The Epidemiology of Cervical Cancer. Cancer Journal (Sudbury, Mass), 2003, 9, 348-359.	1.0	196
26	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months. JAMA - Journal of the American Medical Association, 2018, 320, 43.	3.8	190
27	Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine, 2005, 23, 2388-2394.	1.7	187
28	Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine, 2006, 24, S171-S177.	1.7	183
29	Prevalence, Clearance, and Incidence of Anal Human Papillomavirus Infection in HIVâ€Infected Men: The HIPVIRG Cohort Study. Journal of Infectious Diseases, 2009, 199, 965-973.	1.9	176
30	Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis. International Journal of Cancer, 2013, 133, 1271-1285.	2.3	171
31	A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. International Journal of Cancer, 2003, 106, 896-904.	2.3	159
32	Enhanced Detection and Typing of Human Papillomavirus (HPV) DNA in Anogenital Samples with PGMY Primers and the Linear Array HPV Genotyping Test. Journal of Clinical Microbiology, 2006, 44, 1998-2006.	1.8	157
33	p53 Codon 72 Polymorphism and Cervical Neoplasia: A Meta-Analysis Review. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 11-22.	1.1	153
34	Use of PGMY Primers in L1 Consensus PCR Improves Detection of Human Papillomavirus DNA in Genital Samples. Journal of Clinical Microbiology, 2002, 40, 902-907.	1.8	152
35	Typeâ€Specific Duration of Human Papillomavirus Infection: Implications for Human Papillomavirus Screening and Vaccination. Journal of Infectious Diseases, 2008, 197, 1436-1447.	1.9	151
36	HAART and Progression to High-Grade Anal Intraepithelial Neoplasia in Men Who Have Sex with Men and Are Infected with HIV. Clinical Infectious Diseases, 2011, 52, 1174-1181.	2.9	143

#	Article	IF	Citations
37	Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine, 2007, 25, 6257-6270.	1.7	139
38	World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2-3 and screen-and-treat strategies to prevent cervical cancer. International Journal of Gynecology and Obstetrics, 2016, 132, 252-258.	1.0	134
39	Lateness of diagnosis of oral and oropharyngeal carcinoma: Factors related to the tumour, the patient and health professionals. European Journal of Cancer Part B, Oral Oncology, 1994, 30, 167-173.	0.9	131
40	Multiparameter Calibration of a Natural History Model of Cervical Cancer. American Journal of Epidemiology, 2007, 166, 137-150.	1.6	131
41	Viral load as a predictor of the risk of cervical intraepithelial neoplasia. International Journal of Cancer, 2003, 103, 519-524.	2.3	129
42	The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 485-90.	1.1	129
43	Associations between Cigarette Smoking and Each of 21 Types of Cancer: A Multi-Site Case-Control Study. International Journal of Epidemiology, 1995, 24, 504-514.	0.9	124
44	A MICROCOMPUTER PROGRAM FOR MULTIPLE LOGISTIC REGRESSION BY UNCONDITIONAL AND CONDITIONAL MAXIMUM LIKELIHOOD METHODS1. American Journal of Epidemiology, 1989, 129, 439-444.	1.6	123
45	Human Papillomavirus Infection and Reinfection in Adult Women: the Role of Sexual Activity and Natural Immunity. Cancer Research, 2010, 70, 8569-8577.	0.4	122
46	Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: Data from the ATHENA trial. Gynecologic Oncology, 2015, 137, 47-54.	0.6	121
47	Chapter 13: Primary Screening of Cervical Cancer With Human Papillomavirus Tests. Journal of the National Cancer Institute Monographs, 2003, 2003, 89-96.	0.9	119
48	Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis. Journal of the National Cancer Institute, 2012, 104, 1712-1723.	3.0	119
49	Influence of Postoperative Infectious Complications on Long-Term Survival of Lung Cancer Patients: A Population-Based Cohort Study. Journal of Thoracic Oncology, 2013, 8, 554-561.	0.5	116
50	Human papillomavirus infection and oral cancer: A case-control study in Montreal, Canada. Oral Oncology, 2008, 44, 242-250.	0.8	113
51	Outcomes and Cost Comparisons After Introducing a Robotics Program for Endometrial Cancer Surgery. Obstetrics and Gynecology, 2012, 119, 717-724.	1.2	112
52	Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity. Journal of Infectious Diseases, 2011, 204, 372-376.	1.9	110
53	Modeling the Sexual Transmissibility of Human Papillomavirus Infection using Stochastic Computer Simulation and Empirical Data from a Cohort Study of Young Women in Montreal, Canada. American Journal of Epidemiology, 2006, 163, 534-543.	1.6	108
54	Defining the genetic susceptibility to cervical neoplasiaâ€"A genome-wide association study. PLoS Genetics, 2017, 13, e1006866.	1.5	105

#	Article	IF	CITATIONS
55	Reproductive Health of Adolescent Girls Perinatally Infected With HIV. American Journal of Public Health, 2007, 97, 1047-1052.	1.5	104
56	The Expected Impact of HPV Vaccination on the Accuracy of Cervical Cancer Screening: The Need for a Paradigm Change. Archives of Medical Research, 2009, 40, 478-485.	1.5	104
57	Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine, 2008, 26, A16-A23.	1.7	103
58	Making Prospective Registration of Observational Research a Reality. Science Translational Medicine, 2014, 6, 224cm1.	5.8	99
59	Family history of cancer is a risk factor for squamous cell carcinoma of the head and neck in Brazil: A caseâ€control study. International Journal of Cancer, 1995, 63, 769-773.	2.3	98
60	Use of nonsteroidal antiâ€inflammatory drugs and prostate cancer risk: A metaâ€analysis. International Journal of Cancer, 2010, 127, 1680-1691.	2.3	95
61	Effect of Smoking Cessation and Tobacco Type on the Risk of Cancers of the Upper Aero-Digestive Tract in Brazil. Epidemiology, 1999, 10, 412-418.	1.2	94
62	Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. International Journal of Cancer, 2006, 119, 1389-1395.	2.3	94
63	Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: Design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). International Journal of Cancer, 2006, 119, 615-623.	2.3	93
64	Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatric Blood and Cancer, 2008, 51, 468-474.	0.8	91
65	Maté, Coffee, and Tea Consumption and Risk of Cancers of the Upper Aerodigestive Tract in Southern Brazil. Epidemiology, 1994, 5, 583-590.	1.2	90
66	p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. International Journal of Cancer, 2000, 87, 528-533.	2.3	90
67	Epidemiologic Approaches to Evaluating the Potential for Human Papillomavirus Type Replacement Postvaccination. American Journal of Epidemiology, 2013, 178, 625-634.	1.6	87
68	Introduction of molecular HPV testing as the primary technology in cervical cancer screening: Acting on evidence to change the current paradigm. Preventive Medicine, 2017, 98, 5-14.	1.6	87
69	Age and lateness of referral as determinants of extra-ocular retinoblastoma. Ophthalmic Paediatrics and Genetics, 1989, 10, 179-184.	0.4	81
70	Predictive Factors for Diagnosis of Advanced-Stage Squamous Cell Carcinoma of the Head and Neck. JAMA Otolaryngology, 2002, 128, 313.	1.5	81
71	Assessing the gain in diagnostic performance when combining two diagnostic tests. Statistics in Medicine, 2002, 21, 2527-2546.	0.8	81
72	The Sexually Transmitted Disease Model for Cervical Cancer. Epidemiology, 1991, 2, 98-106.	1.2	80

#	Article	IF	Citations
73	Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual Couples. Journal of Infectious Diseases, 2011, 204, 1723-1729.	1.9	80
74	The psychosocial impact of an abnormal cervical smear result. Psycho-Oncology, 2012, 21, 1071-1081.	1.0	80
7 5	Design and methods of the Ludwig-McGill longitudinal study of the natural history of human papillomavirus infection and cervical neoplasia in Brazil. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 1999, 6, 223-233.	0.6	80
76	Advances in Prevention of Cervical Cancer and Other Human Papillomavirus-Related Diseases. Pediatric Infectious Disease Journal, 2006, 25, S65-S81.	1.1	77
77	Use of Dipyrone during Pregnancy and Risk of Wilms $\hat{E}^{1}/4$ Tumor. Epidemiology, 1996, 7, 533-535.	1.2	76
78	Dietary Intake and Risk of Persistent Human Papillomavirus (HPV) Infection: The Ludwigâ€McGill HPV Natural History Study. Journal of Infectious Diseases, 2003, 188, 1508-1516.	1.9	76
79	Periodontal diseases and risk of oral cancer in Southern India: Results from the HeNCe Life study. International Journal of Cancer, 2016, 139, 1512-1519.	2.3	76
80	Prognostic significance of lymph node variables and human papillomavirus DNA in invasive vulvar carcinoma. Gynecologic Oncology, 2004, 92, 856-865.	0.6	75
81	Presentation Risk factors for second cancers of the upper respiratory and digestive systems: A case-control study. Journal of Clinical Epidemiology, 1991, 44, 615-625.	2.4	74
82	Human Papillomavirus Infections Among Couples in New Sexual Relationships. Epidemiology, 2010, 21, 31-37.	1.2	74
83	Modifiable Risk Factors Associated with Clearance of Type-Specific Cervical Human Papillomavirus Infections in a Cohort of University Students. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1149-1156.	1.1	72
84	Potential costâ€effectiveness of the nonavalent human papillomavirus (HPV) vaccine. International Journal of Cancer, 2014, 134, 2264-2268.	2.3	72
85	Cervical cancer screening of HPV vaccinated populations: Cytology, molecular testing, both or none. Journal of Clinical Virology, 2016, 76, S62-S68.	1.6	72
86	Occurrence of Cervical Infection with Multiple Human Papillomavirus Types is Associated with Age and Cytologic Abnormalities. Sexually Transmitted Diseases, 2003, 30, 581-587.	0.8	70
87	HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPVâ€based primary screening to liquidâ€based cytology for cervical cancer. International Journal of Cancer, 2017, 140, 440-448.	2.3	70
88	Predicted longâ€term impact of <scp>COVID</scp> â€19 pandemicâ€related care delays on cancer mortality in Canada. International Journal of Cancer, 2022, 150, 1244-1254.	2.3	69
89	Parental Exposures to Pesticides and Risk of Wilms' Tumor in Brazil. American Journal of Epidemiology, 1995, 141, 210-217.	1.6	68
90	A randomized controlled trial of Human Papillomavirus (HPV) testing for cervicalcancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer, 2010, 10, 111.	1,1	68

#	Article	IF	Citations
91	The Impact of Anogenital Warts on Health-Related Quality of Life: A 6-Month Prospective Study. Sexually Transmitted Diseases, 2011, 38, 949-956.	0.8	68
92	Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer, 1999, 85, 1903-1909.	2.0	67
93	The effect of cervical loop electrosurgical excision on subsequent pregnancy outcome: North American experience. American Journal of Obstetrics and Gynecology, 1995, 172, 1246-1250.	0.7	66
94	Human leukocyte antigen G polymorphism is associated with an increased risk of invasive cancer of the uterine cervix. International Journal of Cancer, 2012, 131, E312-9.	2.3	64
95	Conventional Cervical Cytologic Smears vs. ThinPrep Smears. Acta Cytologica, 1996, 40, 1136-1142.	0.7	63
96	Determinants of Low-Risk and High-Risk Cervical Human Papillomavirus Infections in Montreal University Students. Sexually Transmitted Diseases, 2000, 27, 79-86.	0.8	62
97	Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. Journal of Medical Virology, 2011, 83, 1034-1041.	2.5	61
98	Human papillomavirus testing versus cytology in primary cervical cancer screening: Endâ€ofâ€study and extended followâ€up results from the Canadian cervical cancer screening trial. International Journal of Cancer, 2016, 139, 2456-2466.	2.3	54
99	Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract., 1999, 85, 1903-1909.		53
100	Aetiological heterogeneity of head and neck squamous cell carcinomas: the role of human papillomavirus infections, smoking and alcohol. Carcinogenesis, 2017, 38, 1188-1195.	1.3	53
101	Polymorphisms of the Human Leukocyte Antigen DRB1 and DQB1 Genes and the Natural History of Human Papillomavirus Infection. Journal of Infectious Diseases, 2002, 186, 164-172.	1.9	51
102	Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16. International Journal of Cancer, 2015, 136, E638-45.	2.3	51
103	Race and gender influences on the survival of patients with mouth cancer. Journal of Clinical Epidemiology, 1993, 46, 37-46.	2.4	50
104	Human leukocyte antigen (HLA)-E and HLA-G polymorphisms in human papillomavirus infection susceptibility and persistence. Human Immunology, 2011, 72, 337-341.	1.2	50
105	Nonisotopic Detection and Typing of Human Papillomavirus DNA in Genital Samples by the Line Blot Assay. Journal of Clinical Microbiology, 1999, 37, 1852-1857.	1.8	50
106	Human papillomavirus infection in postmenopausal women with and without hormone therapy. Obstetrics and Gynecology, 1997, 90, 7-11.	1.2	49
107	Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. European Journal of Cancer Prevention, 2006, 15, 158-164.	0.6	49
108	Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: A transmission-dynamic modelling study. Vaccine, 2014, 32, 5845-5853.	1.7	49

#	Article	IF	Citations
109	Silver leaf nylon dressing to prevent radiation dermatitis in patients undergoing chemotherapy and external beam radiotherapy to the perineum. International Journal of Radiation Oncology Biology Physics, 2004, 59, 809-814.	0.4	48
110	Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: A multi-regional health economic analysis. Vaccine, 2008, 26, F46-F58.	1.7	48
111	Use of Non-Steroidal Anti-Inflammatory Drugs and Prostate Cancer Risk: A Population-Based Nested Case-Control Study. PLoS ONE, 2011, 6, e16412.	1.1	47
112	Oncogenic Human Papillomavirus Infection and Cervical Lesions in Aboriginal Women of Nunavut, Canada. Sexually Transmitted Diseases, 2001, 28, 694-700.	0.8	46
113	Towards More Effective Public Health Programming for Injection Drug Users: Development and Evaluation of the Injection Drug User Quality of Life Scale. Substance Use and Misuse, 2003, 38, 965-992.	0.7	45
114	Polio vaccines, Simian Virus 40, and human cancer: the epidemiologic evidence for a causal association. Oncogene, 2004, 23, 6535-6540.	2.6	45
115	Persistence of an Incident Human Papillomavirus Infection and Timing of Cervical Lesions in Previously Unexposed Young Women. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 854-862.	1.1	45
116	Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infectious Diseases, 2010, 10, 326.	1.3	45
117	Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women. Pediatrics, 2019, 143, .	1.0	45
118	Evaluation of the potential carcinogenicity of 60 Hz linear sinusoidal continuousâ€wave magnetic fields in Fischer F344 rats. FASEB Journal, 1997, 11, 1127-1136.	0.2	45
119	Prognostic factors in laryngeal cancer patients submitted to surgical treatment. Journal of Surgical Oncology, 1991, 48, 87-95.	0.8	44
120	Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage of women with cervical cytologic abnormalities. American Journal of Obstetrics and Gynecology, 1999, 181, 382-386.	0.7	44
121	Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine, 2006, 24, S251-S261.	1.7	44
122	Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean. Vaccine, 2008, 26, L96-L107.	1.7	44
123	No role for human papillomavirus infection in oral cancers in a region in southern <scp>I</scp> ndia. International Journal of Cancer, 2016, 138, 912-917.	2.3	44
124	Substantial Decline in Vaccine-Type Human Papillomavirus (HPV) Among Vaccinated Young Women During the First 8 Years After HPV Vaccine Introduction in a Community. Clinical Infectious Diseases, 2016, 63, 1281-1287.	2.9	44
125	Mobile Screening Units for the Early Detection of Cancer: A Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1679-1694.	1.1	44
126	Effect of type of alcoholic beverage on the risks of upper aerodigestive tract cancers in Brazil. Cancer Causes and Control, 2001, 12, 579-587.	0.8	43

#	Article	IF	Citations
127	Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: A transmission-dynamic modeling study. Vaccine, 2013, 31, 3863-3871.	1.7	43
128	Women's intentions to receive cervical cancer screening with primary human papillomavirus testing. International Journal of Cancer, 2013, 133, 2934-2943.	2.3	43
129	Confirmatory Real-Time PCR Assay for Human Papillomavirus (HPV) Type 52 Infection in Anogenital Specimens Screened for HPV Infection with the Linear Array HPV Genotyping Test. Journal of Clinical Microbiology, 2007, 45, 3821-3823.	1.8	42
130	Intensity of drug injection as a determinant of sustained injection cessation among chronic drug users: the interface with social factors and service utilization. Addiction, 2004, 99, 727-737.	1.7	40
131	Integration of Human Papillomavirus Vaccination and Cervical Cancer Screening in Latin America and the Caribbean. Vaccine, 2008, 26, L88-L95.	1.7	40
132	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, F1-F31.	1.7	40
133	The future burden of cancer in Canada: Long-term cancer incidence projections 2013–2042. Cancer Epidemiology, 2019, 59, 199-207.	0.8	40
134	Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus–Based Screening in Mexico. JAMA Network Open, 2019, 2, e1915781.	2.8	40
135	High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. Journal of Medical Virology, 2006, 78, 814-819.	2.5	39
136	Genotyping of Human Papillomavirus DNA in Anal Biopsies and Anal Swabs Collected From HIV-Seropositive Men With Anal Dysplasia. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 49, 32-39.	0.9	39
137	Influence of Partner's Infection Status on Prevalent Human Papillomavirus Among Persons With a New Sex Partner. Sexually Transmitted Diseases, 2010, 37, 34-40.	0.8	39
138	Dietary consumption of antioxidant nutrients and risk of incident cervical intraepithelial neoplasia. Gynecologic Oncology, 2010, 118, 289-294.	0.6	39
139	Does hormonal therapy for fertility preservation affect the survival of young women with earlyâ€stage endometrial cancer?. Cancer, 2017, 123, 1545-1554.	2.0	39
140	Optimizing secondary prevention of cervical cancer: RecentÂadvances and future challenges. International Journal of Gynecology and Obstetrics, 2017, 138, 15-19.	1.0	39
141	Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated women: a modelling study. Lancet Oncology, The, 2018, 19, 1569-1578.	5.1	39
142	Global estimates of expected and preventable cervical cancers among girls born between 2005 and 2014: a birth cohort analysis. Lancet Public Health, The, 2021, 6, e510-e521.	4.7	39
143	Factors Influencing Regional Lymph Node Metastasis from Laryngeal Carcinoma. Annals of Otology, Rhinology and Laryngology, 1995, 104, 442-447.	0.6	38
144	Prevalence and Age Distribution of Human Papillomavirus Infection in a Population of Inuit Women in Nunavik, Quebec. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3141-3149.	1.1	38

#	Article	IF	CITATIONS
145	Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer, 2015, 15, 968.	1.1	38
146	HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status. Cancer Cytopathology, 2015, 123, 745-754.	1.4	37
147	Herpes simplex virus type II is not a cofactor to human papillomavirus in cancer of the uterine cervix. American Journal of Obstetrics and Gynecology, 2003, 188, 129-134.	0.7	36
148	HLA Polymorphisms and Cervical Human Papillomavirus Infection in a Cohort of Montreal University Students. Journal of Infectious Diseases, 2007, 196, 82-90.	1.9	36
149	Lung Cancer Screening: Review and Performance Comparison Under Different Risk Scenarios. Lung, 2014, 192, 55-63.	1.4	36
150	Sexual Transmission of Oral Human Papillomavirus Infection among Men. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2959-2964.	1.1	36
151	Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval. BMC Public Health, 2016, 16, 213.	1.2	36
152	Innovations in understanding the biology of cervical cancer. Cancer, 2003, 98, 2064-2069.	2.0	35
153	Comparison of Psychosocial Outcomes in Head and Neck Cancer Patients Receiving a Coping Strategies Intervention and Control Subjects Receiving No Intervention. The Journal of Otolaryngology, 2006, 35, 88.	0.6	35
154	Human Papillomavirus and Cancer Prevention: Gaps in Knowledge and Prospects for Research, Policy, and Advocacy. Vaccine, 2012, 30, F175-F182.	1.7	35
155	The future of HPV testing in clinical laboratories and applied virology research. Clinical and Diagnostic Virology, 1997, 8, 123-141.	1.8	34
156	The p53 codon 72 polymorphism and risk of high-grade cervical intraepithelial neoplasia. Cancer Detection and Prevention, 2005, 29, 307-316.	2.1	34
157	The Laboratory Diagnosis of Genital Human Papillomavirus Infections. Canadian Journal of Infectious Diseases and Medical Microbiology, 2005, 16, 83-91.	0.7	34
158	Determinants of delays in treatment initiation in children and adolescents diagnosed with leukemia or lymphoma in Canada. International Journal of Cancer, 2010, 126, 1936-1943.	2.3	34
159	Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-na $ ilde{A}$ -ve women: results from the control arm of a phase II HPV-16/18 vaccine trial. BMJ Open, 2016, 6, e011371.	0.8	34
160	Approaches for triaging women who test positive for human papillomavirus in cervical cancer screening. Preventive Medicine, 2017, 98, 15-20.	1.6	34
161	Human papillomavirus and cervical cancer: burden of illness and basis for prevention. American Journal of Managed Care, 2006, 12, S462-72.	0.8	34
162	Absence of Relationship between Health Effects Due to Tap Water Consumption and Drinking Water Quality Parameters. Water Science and Technology, 1993, 27, 137-143.	1.2	33

#	Article	IF	CITATIONS
163	Human Papillomavirus Type 33 Polymorphisms and Highâ€Grade Squamous Intraepithelial Lesions of the Uterine Cervix. Journal of Infectious Diseases, 2006, 194, 886-894.	1.9	33
164	Selected class I and class II HLA alleles and haplotypes and risk of highâ€grade cervical intraepithelial neoplasia. International Journal of Cancer, 2008, 122, 2820-2826.	2.3	33
165	Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine, 2013, 31, G1-G31.	1.7	33
166	Global Genomic Diversity of Human Papillomavirus 6 Based on 724 Isolates and 190 Complete Genome Sequences. Journal of Virology, 2014, 88, 7307-7316.	1.5	33
167	Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial. Journal of Clinical Virology, 2017, 87, 23-29.	1.6	33
168	Characterization of the Vaginal Microbiome in Women of Reproductive Age From 5 Regions in Brazil. Sexually Transmitted Diseases, 2020, 47, 562-569.	0.8	33
169	Cancer of the Uterine Cervix. BMC Women's Health, 2004, 4, S13.	0.8	32
170	The impact of intolerance of uncertainty on anxiety after receiving an informational intervention about HPV: A randomised controlled study. Psychology and Health, 2010, 25, 651-668.	1.2	31
171	Correlation patterns of cancer relative frequencies with some socioeconomic and demographic indicators in Brazil: An ecologic study. International Journal of Cancer, 1988, 41, 24-29.	2.3	30
172	Etiology of Wilms' Tumor. Epidemiologic Reviews, 1995, 17, 415-432.	1.3	30
173	Clinical significance of histiocytes in the detection of endometrial adenocarcinoma and hyperplasia. Diagnostic Cytopathology, 1998, 19, 89-93.	0.5	30
174	Interaction between polymorphisms of the Human Leukocyte Antigen and HPV-16 Variants on the risk of invasive cervical cancer. BMC Cancer, 2008, 8, 246.	1.1	30
175	Human papillomavirus type 16 viral load measurement as a predictor of infection clearance. Journal of General Virology, 2013, 94, 1850-1857.	1.3	30
176	Cervical-cancer screening beyond the year 2000. Lancet Oncology, The, 2001, 2, 27-32.	5.1	29
177	Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sexual Health, 2010, 7, 376.	0.4	29
178	The association between human leukocyte antigen (HLA)-G polymorphisms and human papillomavirus (HPV) infection in Inuit women of northern Quebec. Human Immunology, 2013, 74, 1610-1615.	1.2	29
179	Assessment of mediators of racial disparities in cervical cancer survival in the <scp>U</scp> nited <scp>S</scp> tates. International Journal of Cancer, 2016, 138, 2622-2630.	2.3	29
180	Estimating the current and future cancer burden in Canada: methodological framework of the Canadian population attributable risk of cancer (ComPARe) study. BMJ Open, 2018, 8, e022378.	0.8	29

#	Article	IF	CITATIONS
181	Predictors of cervical coinfection with multiple human papillomavirus types. Cancer Epidemiology Biomarkers and Prevention, 2003, 12, 1029-37.	1.1	29
182	Evidence-based policy recommendations on cancer screening and prevention. Cancer Detection and Prevention, 2002, 26, 350-361.	2.1	28
183	Incidence of Norwalk virus infections during a prospective epidemiological study of drinking water related gastrointestinal illness. Canadian Journal of Microbiology, 1994, 40, 805-809.	0.8	27
184	Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction. Human Vaccines and Immunotherapeutics, 2019, 15, 1962-1969.	1.4	27
185	Human Papillomavirus Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study: Protocol Describing Design, Methods, and Research Goals. JMIR Research Protocols, 2019, 8, e11284.	0.5	27
186	Nonlinear association between betel quid chewing and oral cancer: Implications for prevention. Oral Oncology, 2016, 60, 25-31.	0.8	26
187	Non–Vaccine-Type Human Papillomavirus Prevalence After Vaccine Introduction: No Evidence for Type Replacement but Evidence for Cross-Protection. Sexually Transmitted Diseases, 2018, 45, 260-265.	0.8	26
188	Triage strategies in cervical cancer detection in Mexico: methods of the FRIDA Study. Salud Publica De Mexico, 2016, 58, 197-210.	0.1	26
189	Statistical Issues in Human Papillomavirus Testing and Screening. Clinics in Laboratory Medicine, 2000, 20, 345-367.	0.7	25
190	Role and limitations of epidemiology in establishing a causal association. Seminars in Cancer Biology, 2004, 14, 413-426.	4.3	25
191	Estimating HPV DNA Deposition Between Sexual Partners Using HPV Concordance, Y Chromosome DNA Detection, and Self-reported Sexual Behaviors. Journal of Infectious Diseases, 2017, 216, 1210-1218.	1.9	25
192	An Oocyst-Transmitted Outbreak of Toxoplasmosis: Patterns of Immunoglobulin G and M over One Year. American Journal of Tropical Medicine and Hygiene, 1986, 35, 290-296.	0.6	25
193	The Role of Human Papillomaviruses in Cancer. American Journal of Cancer, 2005, 4, 49-64.	0.4	24
194	Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 716-722.	1.1	24
195	Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of High-Grade Lesions of the Uterine Cervix. Journal of Clinical Microbiology, 2012, 50, 1240-1244.	1.8	24
196	Epidemiology, natural history and risk factors for anal intraepithelial neoplasia. Sexual Health, 2012, 9, 547.	0.4	24
197	Evaluation of Human Papillomavirus Type Replacement Postvaccination Must Account for Diagnostic Artifacts: Masking of HPV52 by HPV16 in Anogenital Specimens. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 286-290.	1.1	24
198	Human papillomavirus genotypes and risk of head and neck cancers: Results from the HeNCe Life case-control study. Oral Oncology, 2017, 69, 56-61.	0.8	24

#	Article	IF	Citations
199	Determinants of Cervical Cancer Screening Accuracy for Visual Inspection with Acetic Acid (VIA) and Lugol's Iodine (VILI) Performed by Nurse and Physician. PLoS ONE, 2017, 12, e0170631.	1.1	24
200	Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion. Journal of Clinical Virology, 2006, 36, 133-140.	1.6	23
201	Human papillomavirus testing with Pap triage for cervical cancer prevention in Canada: a cost-effectiveness analysis. BMC Medicine, 2009, 7, 69.	2.3	23
202	Are endometrial polyps true cancer precursors?. American Journal of Obstetrics and Gynecology, 2010, 203, 232.e1-232.e6.	0.7	23
203	Associations of dietary dark-green and deep-yellow vegetables and fruits with cervical intraepithelial neoplasia: modification by smoking. British Journal of Nutrition, 2011, 105, 928-937.	1.2	23
204	Inuit women's attitudes and experiences towards cervical cancer and prevention strategies in Nunavik, Quebec. International Journal of Circumpolar Health, 2012, 71, 17996.	0.5	23
205	Predictive Value of HPV Testing in Self-collected and Clinician-Collected Samples Compared with Cytology in Detecting High-grade Cervical Lesions. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1134-1140.	1.1	23
206	Loss of quality of life associated with genital warts: baseline analyses from a prospective study. Sexually Transmitted Infections, 2011, 87, 209-215.	0.8	22
207	HLAandKIRAssociations of Cervical Neoplasia. Journal of Infectious Diseases, 2018, 218, 2006-2015.	1.9	22
208	Episomal and integrated human papillomavirus type 16 loads and anal intraepithelial neoplasia in HIV-seropositive men. Aids, 2010, 24, 2355-2363.	1.0	22
209	Associations between serum carotenoids and tocopherols and type-specific HPV persistence: The Ludwig-McGill cohort study. International Journal of Cancer, 2007, 120, 672-680.	2.3	21
210	cobas ^{$\hat{A}^{@}$} 4800 HPV Test, a real-time polymerase chain reaction assay for the detection of human papillomavirus in cervical specimens. Expert Review of Molecular Diagnostics, 2014, 14, 5-16.	1.5	21
211	Determinants of Prevalent Human Papillomavirus in Recently Formed Heterosexual Partnerships: A Dyadic-Level Analysis. Journal of Infectious Diseases, 2014, 210, 846-852.	1.9	21
212	Comparison of Triage Strategies for HPV-Positive Women: Canadian Cervical Cancer Screening Trial Results. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 923-929.	1.1	21
213	A randomized clinical trial of single-dose versus fractionated-dose dactinomycin in the treatment of wilms' tumor. Results after extended follow-up. Cancer, 1994, 73, 3081-3086.	2.0	20
214	Use of the Normalized Absorbance Ratio as an Internal Standardization Approach To Minimize Measurement Error in Enzyme-Linked Immunosorbent Assays for Diagnosis of Human Papillomavirus Infection. Journal of Clinical Microbiology, 2010, 48, 791-796.	1.8	20
215	Economic evaluation of strategies for managing women with equivocal cytological results in Brazil. International Journal of Cancer, 2011, 129, 671-679.	2.3	20
216	Polymorphism in the promoter region of the Toll-like receptor 9 gene and cervical human papillomavirus infection. Journal of General Virology, 2013, 94, 1858-1864.	1.3	20

#	Article	IF	CITATIONS
217	Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial. Journal of Clinical Virology, 2018, 108, 32-37.	1.6	20
218	Chapter 29: Knowledge gaps and priorities for research on prevention of HPV infection and cervical cancer. Vaccine, 2006, 24, S242-S249.	1.7	19
219	Prevalence and Determinants of High-Risk Human Papillomavirus Infection in Women From a Sub-Saharan African Community. Sexually Transmitted Diseases, 2011, 38, 308-315.	0.8	19
220	Human papillomavirus vaccination and the role of herd effects in future cancer control planning: a review. Expert Review of Vaccines, 2018, 17, 395-409.	2.0	19
221	Multiple cancers of the upper aero-digestive tract: the challenge of risk factor identification. Cancer Letters, 1991, 60, 1-8.	3.2	18
222	Comparison of endocervical curettage and endocervical brushing. Obstetrics and Gynecology, 2000, 96, 90-94.	1.2	18
223	Toward a reduction of the global burden of cervical cancer. American Journal of Obstetrics and Gynecology, 2003, 189, S37-S39.	0.7	18
224	Report of the 2003 Pan-Canadian Forum on Cervical Cancer Prevention and Control. Journal of Obstetrics and Gynaecology Canada, 2004, 26, 1004-1014.	0.3	18
225	Cervical cancer screening following the implementation of prophylactic human papillomavirus vaccination. Future Oncology, 2007, 3, 319-327.	1.1	18
226	Haptoglobin phenotype and risk of cervical neoplasia: A case-control study. Clinica Chimica Acta, 2007, 385, 67-72.	0.5	18
227	Human Papillomavirus (HPV) DNA Triage of Women with Atypical Squamous Cells of Undetermined Significance with Amplicor HPV and Hybrid Capture 2 Assays for Detection of High-Grade Lesions of the Uterine Cervix. Journal of Clinical Microbiology, 2011, 49, 48-53.	1.8	18
228	Optimizing technology for cervical cancer screening in high-resource settings. Expert Review of Obstetrics and Gynecology, 2011, 6, 343-353.	0.4	18
229	Circulating Biomarkers of Iron Storage and Clearance of Incident Human Papillomavirus Infection. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 859-865.	1.1	18
230	Comparison of human papillomavirus testing and cytology for cervical cancer screening in a primary health care setting in the Democratic Republic of the Congo. Gynecologic Oncology, 2012, 124, 286-291.	0.6	18
231	Self-Sampling for Cervical Cancer Screening: Empowering Women to Lead a Paradigm Change in Cancer Control. Current Oncology, 2018, 25, 1-3.	0.9	18
232	Determinants of Human Papillomavirus Infection Among Inuit Women of Northern Quebec, Canada. Sexually Transmitted Diseases, 2010, 37, 377-381.	0.8	18
233	Modeling the Time Dependence of the Association between Human Papillomavirus Infection and Cervical Cancer Precursor Lesions. American Journal of Epidemiology, 2003, 158, 878-886.	1.6	17
234	Detection and Typing of Human Papillomavirus Nucleic Acids in Biological Fluids. Public Health Genomics, 2009, 12, 308-318.	0.6	17

#	Article	IF	Citations
235	Polymorphism of the capsid L1 gene of human papillomavirus types 31, 33, and 35. Journal of Medical Virology, 2010, 82, 1168-1178.	2.5	17
236	Predictors of preoperative delays before radical cystectomy for bladder cancer in <scp>Q</scp> uebec, <scp>C</scp> anada: a populationâ€based study. BJU International, 2015, 115, 389-396.	1.3	17
237	Reproductive and genital health and risk of cervical human papillomavirus infection: results from the Ludwig-McGill cohort study. BMC Infectious Diseases, 2016, 16, 116.	1.3	17
238	A Review of Canadian Cancer-Related Clinical Practice Guidelines and Resources during the COVID-19 Pandemic. Current Oncology, 2021, 28, 1020-1033.	0.9	17
239	Epidemiologic Evaluation of Human Papillomavirus Type Competition and the Potential for Type Replacement Post-Vaccination. PLoS ONE, 2016, 11, e0166329.	1.1	17
240	ARE THE APPARENT EFFECTS OF CIGARETTE SMOKING ON LUNG AND BLADDER CANCERS DUE TO UNCONTROLLED CONFOUNDING BY OCCUPATIONAL EXPOSURES?. Epidemiology, 1994, 5, 57-65.	1.2	16
241	Risk behaviour change and HIV infection among injection drug users in Montreal. Aids, 2000, 14, 2575-2582.	1.0	16
242	Influence of human papillomavirus type 16 (HPV-16) E2 polymorphism on quantification of HPV-16 episomal and integrated DNA in cervicovaginal lavages from women with cervical intraepithelial neoplasia. Journal of General Virology, 2008, 89, 1716-1728.	1.3	16
243	Integrating Human Papillomavirus Vaccination in Cervical Cancer Control Programmes. Public Health Genomics, 2009, 12, 352-361.	0.6	16
244	What is the role of HPV typing in the United States now and in the next five years in a vaccinated population?. Gynecologic Oncology, 2010, 117, 481-485.	0.6	16
245	Polymorphisms in Genes Involved in Folate Metabolism Modify the Association of Dietary and Circulating Folate and Vitamin B-6 with Cervical Neoplasia. Journal of Nutrition, 2013, 143, 2007-2014.	1.3	16
246	Prevention and control of HPV infection and HPV-related cancers in Colombia- a meeting report. BMC Proceedings, 2020, 14, 8.	1.8	16
247	Prospects for controlling cervical cancer at the turn of the century. Salud Publica De Mexico, 2003, 45, 367-375.	0.1	16
248	Association between timing of surgery during menstrual cycle and prognosis in pre-menopausal breast cancer. International Journal of Cancer, 1993, 53, 707-708.	2.3	15
249	HIV-Positive Notification and Behavior Changes in Montreal Injection Drug Users. AIDS Education and Prevention, 2002, 14, 17-28.	0.6	15
250	A New Generation of Studies of Human Papillomavirus DNA Testing in Cervical Cancer Screening. Journal of the National Cancer Institute, 2009, 101, 1600-1601.	3.0	15
251	Counterpoint: Cervical Cancer Screening GuidelinesApproaching the Golden Age. American Journal of Epidemiology, 2013, 178, 1023-1026.	1.6	15
252	Human papillomavirus type 52 polymorphism and highâ€grade lesions of the uterine cervix. International Journal of Cancer, 2013, 132, 1821-1830.	2.3	15

#	Article	IF	CITATIONS
253	Determinants of Human Papillomavirus Coinfections among Montreal University Students: The Influence of Behavioral and Biologic Factors. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 812-822.	1.1	15
254	Embracing a new era in cervical cancer screening. Lancet, The, 2014, 383, 493-494.	6.3	15
255	Incidence, Persistence, and Determinants of Human Papillomavirus Infection in a Population of Inuit Women in Northern Quebec. Sexually Transmitted Diseases, 2015, 42, 272-278.	0.8	15
256	Population-based prevalence of cervical infection with human papillomavirus genotypes 16 and 18 and other high risk types in Tlaxcala, Mexico. BMC Infectious Diseases, 2016, 16, 461.	1.3	15
257	Genomeâ€wide DNA methylation profiling identifies two novel genes in cervical neoplasia. International Journal of Cancer, 2020, 147, 1264-1274.	2.3	15
258	Are we ready for a paradigm change in cervical cancer screening?. Lancet, The, 2003, 362, 1866-1867.	6.3	14
259	Viral load of episomal and integrated forms of human papillomavirus type 33 in highâ€grade squamous intraepithelial lesions of the uterine cervix. International Journal of Cancer, 2007, 121, 2674-2681.	2.3	14
260	Factors associated with cervical cancer screening uptake among Inuit women in Nunavik, Quebec, Canada. BMC Public Health, 2013, 13, 438.	1.2	14
261	Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study. Gynecologic Oncology, 2018, 149, 491-497.	0.6	14
262	The burden of cancer attributable to modifiable risk factors in Canada: Methods overview. Preventive Medicine, 2019, 122, 3-8.	1.6	14
263	Hand-to-genital and genital-to-genital transmission of human papillomaviruses between male and female sexual partners (HITCH): a prospective cohort study. Lancet Infectious Diseases, The, 2019, 19, 317-326.	4.6	14
264	Cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and metaâ€analysis. International Journal of Cancer, 2020, 147, 2695-2707.	2.3	14
265	Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 22-29.	1.1	14
266	Evaluation of the potential promoting effect of 60 Hz magnetic fields on N-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats. Bioelectromagnetics, 2000, 21, 84-93.	0.9	13
267	Detection of human herpes virus type 6 DNA in precancerous lesions of the uterine cervix. Journal of Medical Virology, 2002, 68, 606-610.	2.5	13
268	Vaccination of Young Women Decreases Human Papillomavirus Transmission in Heterosexual Couples: Findings from the HITCH Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1825-1834.	1.1	13
269	Surgeon and hospital volume outcomes in bariatric surgery: a population-level study. Surgery for Obesity and Related Diseases, 2020, 16, 674-681.	1.0	13
270	Evolution of Public Health Human Papillomavirus Immunization Programs in Canada. Current Oncology, 2021, 28, 991-1007.	0.9	13

#	Article	IF	CITATIONS
271	Management of low-grade cervical lesions in young women. Cmaj, 2005, 173, 771-774.	0.9	12
272	Polymorphism of the L1 Capsid Gene and Persistence of Human Papillomavirus Type 52 Infection in Women at High Risk or Infected by HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 44, 61-65.	0.9	12
273	Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program. BMC Public Health, 2014, 14, 1060.	1.2	12
274	Risk of Human Papillomavirus (HPV) Infection and Cervical Neoplasia after Pregnancy. BMC Pregnancy and Childbirth, 2015, 15, 244.	0.9	12
275	Defining benchmarks for tolerable risk thresholds in cancer screening: Impact of HPV vaccination on the future of cervical cancer screening. International Journal of Cancer, 2020, 147, 3305-3312.	2.3	12
276	Diagnosis of Acute Acquired Toxoplasmosis with the Enzyme-Labelled Antigen Reversed Immunoassay for Immunoglobulin M Antibodies. Journal of Immunoassay, 1983, 4, 373-393.	0.3	11
277	Plasminogen activator expression and steroid hormone receptors in female breast cancer: A multifactorial study. International Journal of Cancer, 1988, 41, 798-804.	2.3	11
278	Past, present, and future of HPV research: highlights from the 19th International Papillomavirus Conference-HPV2001. Virus Research, 2002, 89, 163-173.	1.1	11
279	Male Circumcision and AIDS in Africa. Epidemiology, 2004, 15, 133-134.	1.2	11
280	Commentary: Health inequity could increase in poor countries if universal HPV vaccination is not adopted. BMJ: British Medical Journal, 2007, 335, 378-379.	2.4	11
281	Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program. Journal of Obstetrics and Gynaecology Canada, 2015, 37, 412-420.	0.3	11
282	Human papillomavirus vaccines: key factors in planning cost-effective vaccination programs. Expert Review of Vaccines, 2015, 14, 119-133.	2.0	11
283	Cervical Infection with Cutaneous Beta and Mucosal Alpha Papillomaviruses. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1312-1320.	1.1	11
284	Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age. Gynecologic Oncology, 2019, 155, 245-253.	0.6	11
285	Latency of tobacco smoking for head and neck cancer among HPVâ€positive and HPVâ€negative individuals. International Journal of Cancer, 2020, 147, 56-64.	2.3	11
286	Dual staining for p16/Kiâ€67 to detect highâ€grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study. International Journal of Cancer, 2021, 148, 492-501.	2.3	11
287	Sex- and Type-specific Genital Human Papillomavirus Transmission Rates Between Heterosexual Partners: A Bayesian Reanalysis of the HITCH Cohort. Epidemiology, 2021, 32, 368-377.	1.2	11
288	Modeling Cervical Cancer Screening Strategies With Varying Levels of Human Papillomavirus Vaccination. JAMA Network Open, 2021, 4, e2115321.	2.8	11

#	Article	IF	CITATIONS
289	Performance of an Adipokine Pathway-Based Multilocus Genetic Risk Score for Prostate Cancer Risk Prediction. PLoS ONE, 2012, 7, e39236.	1.1	11
290	Assessment of control selection bias in a hospital-based case-control study of upper aero-digestive tract cancers. Journal of Cancer Epidemiology and Prevention, 2002, 7, 131-41.	1.1	11
291	Single-doseversus fractionated-dose dactinomycin in the treatment of wilms' tumor. Preliminary results of a clinical trial. Cancer, 1991, 67, 2990-2996.	2.0	10
292	Accuracy of p53 Codon 72 Polymorphism Status Determined by Multiple Laboratory Methods: A Latent Class Model Analysis. PLoS ONE, 2013, 8, e56430.	1.1	10
293	Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. British Journal of Cancer, 2016, 115, 1487-1494.	2.9	10
294	Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13–26-Year-Old Young Men After HPV Vaccine Introduction. Journal of Adolescent Health, 2018, 63, 43-49.	1.2	10
295	Human Papillomavirus Viral Load and Transmission in Young, Recently Formed Heterosexual Couples. Journal of Infectious Diseases, 2019, 220, 1152-1161.	1.9	10
296	Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. Sexually Transmitted Diseases, 2019, 46, 663-669.	0.8	10
297	Timeliness of diagnosis and treatment: the challenge of childhood cancers. British Journal of Cancer, 2021, 125, 1612-1620.	2.9	10
298	Carrageenan as a Preventive Agent Against Human Papillomavirus Infection: A Narrative Review. Sexually Transmitted Diseases, 2021, 48, 458-465.	0.8	10
299	Epidemiological and clinical correlations with genetic characteristics of Wilms' tumor: Results of the Brazilian Wilms' tumor study group. International Journal of Cancer, 1991, 48, 641-646.	2.3	9
300	Is HPV testing with cytological triage a more logical approach in cervical cancer screening?. Lancet Oncology, The, 2006, 7, 527-529.	5.1	9
301	Re: Human Papillomavirus Type 16 and 18 Variants: Race-Related Distribution and Persistence. Journal of the National Cancer Institute, 2007, 99, 653-654.	3.0	9
302	Awareness and Knowledge about Human Papillomavirus Among Inuit Women in Nunavik, Quebec. Journal of Community Health, 2011, 36, 56-62.	1.9	9
303	Cervical Infection With Vaccine-Associated Human Papillomavirus (HPV) Genotypes as a Predictor of Acquisition and Clearance of Other HPV Infections. Journal of Infectious Diseases, 2016, 214, 676-684.	1.9	9
304	Cancers attributable to infections in Canada. Preventive Medicine, 2019, 122, 109-117.	1.6	9
305	Increased risk of oropharyngeal cancers mediated by oral human papillomavirus infection: Results from a Canadian study. Head and Neck, 2019, 41, 678-685.	0.9	9
306	Directionality of Genital Human Papillomavirus Infection Transmission Within Heterosexual Couples: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2020, 222, 1928-1937.	1.9	9

#	Article	IF	CITATIONS
307	Costâ€effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. Cancer Medicine, 2021, 10, 2996-3003.	1.3	9
308	Human papillomavirus vaccination in adults: impact, opportunities and challenges – a meeting report. BMC Proceedings, 2021, 15, 16.	1.8	9
309	Proportion of Incident Genital Human Papillomavirus Detections not Attributable to Transmission and Potentially Attributable to Latent Infections: Implications for Cervical Cancer Screening. Clinical Infectious Diseases, 2022, 75, 365-371.	2.9	9
310	Prophylactic human papillomavirus vaccines: potential for sea change. Expert Review of Vaccines, 2007, 6, 511-525.	2.0	8
311	Koilocytosis in Oral Squamous Cell Carcinoma: What Does It Mean?. The Journal of Otolaryngology, 2007, 36, 26.	0.6	8
312	Prognostic Value of Measuring Load of Human Papillomavirus DNA in Cervical Samples: An Elusive Target. Journal of the National Cancer Institute, 2009, 101, 131-133.	3.0	8
313	Burden of disease, health indicators and challenges for epidemiology in North America. International Journal of Epidemiology, 2012, 41, 540-556.	0.9	8
314	An elusive low-hanging fruit for public health: Gun violence prevention. Preventive Medicine, 2015, 79, 1-2.	1.6	8
315	Improving the reporting of cancer-specific mortality and survival in research using cancer registry data. Cancer Epidemiology, 2019, 59, 232-235.	0.8	8
316	Low-risk human papillomavirus type 6 DNA load and integration in cervical samples from women with squamous intraepithelial lesions. Journal of Clinical Virology, 2009, 45, 96-99.	1.6	7
317	No Association between Endogenous Retinoic Acid and Human Papillomavirus Clearance or Incident Cervical Lesions in Brazilian Women. Cancer Prevention Research, 2010, 3, 1007-1014.	0.7	7
318	Invited Commentary: Human Papillomavirus Infection and Risk of Cervical Precancer-Using the Right Methods to Answer the Right Questions. American Journal of Epidemiology, 2010, 171, 164-168.	1.6	7
319	Integrating novel primary- and secondary-prevention strategies: the next challenge for cervical cancer control. Future Oncology, 2010, 6, 1725-1733.	1.1	7
320	Y Chromosome DNA in Women's Vaginal Samples as a Biomarker of Recent Vaginal Sex and Condom Use With Male Partners in the HPV Infection and Transmission Among Couples Through Heterosexual Activity Cohort Study. Sexually Transmitted Diseases, 2018, 45, 28-34.	0.8	7
321	An overview of epidemiological and public health research on HPVs presented at the 21st International Papillomavirus Conference in Mexico City, 20-26 February 2004. Papillomavirus Report, 2004, 15, 121-123.	0.2	7
322	Predictors of dysplastic and neoplastic progression of Barrett's esophagus. Canadian Journal of Surgery, 2019, 62, 93-99.	0.5	7
323	Use of HPV testing in cervical cancer screening services in Mexico, 2008-2018: a nationwide database study. Salud Publica De Mexico, 2018, 60, 722.	0.1	7
324	Vaginal Microbiome Components as Correlates of Cervical Human Papillomavirus Infection. Journal of Infectious Diseases, 2022, 226, 1084-1097.	1.9	7

#	Article	IF	Citations
325	Computer-assisted multiple categorization of absorbance values in ELISA through pictorial emulation of 96-well plates. Journal of Immunological Methods, 1984, 70, 45-52.	0.6	6
326	Randomized controlled trials of HPV testing and pap cytology: Toward evidence-based cervical cancer prevention. International Journal of Cancer, 2004, 110, 1-2.	2.3	6
327	Use of latent class models to accommodate inter-laboratory variation in assessing genetic polymorphisms associated with disease risk. BMC Genetics, 2008, 9, 51.	2.7	6
328	Ovarian cancer and oral contraceptives. Lancet, The, 2008, 371, 277-278.	6.3	6
329	Epidemiology's Contributions to a Nobel Prize Recognition. Epidemiology, 2009, 20, 632-634.	1.2	6
330	The frequency of HLA alleles in a population of Inuit women of northern Quebec. International Journal of Circumpolar Health, 2013, 72, 21350.	0.5	6
331	Determinants of baseline seroreactivity to human papillomavirus type 16 in the Ludwig-McGill cohort study. BMC Infectious Diseases, 2014, 14, 578.	1.3	6
332	Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial. Journal of Obstetrics and Gynaecology Canada, 2016, 38, 723-726.	0.3	6
333	The Downside of the Shifting Paradigm of Scholarly Publishing in the Biomedical Sciences: Predatory Publishing. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 513-515.	0.3	6
334	Assortativity and Mixing by Sexual Behaviors and Sociodemographic Characteristics in Young Adult Heterosexual Dating Partnerships. Sexually Transmitted Diseases, 2017, 44, 329-337.	0.8	6
335	Decline in vaccine-type human papillomavirus prevalence in young men from a Midwest metropolitan area of the United States over the six years after vaccine introduction. Vaccine, 2019, 37, 6832-6841.	1.7	6
336	A Pooled Analysis to Compare the Clinical Characteristics of Human Papillomavirus–positive and -Negative Cervical Precancers. Cancer Prevention Research, 2020, 13, 829-840.	0.7	6
337	Transmission reduction and prevention with HPV vaccination (TRAP-HPV) study protocol: a randomised controlled trial of the efficacy of HPV vaccination in preventing transmission of HPV infection in heterosexual couples. BMJ Open, 2020, 10, e039383.	0.8	6
338	Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results. BMJ Open, 2021, 11, e052084.	0.8	6
339	Cervix., 2002,, 249-286.		5
340	Evaluation of a convenient enzyme immunoassay to assess the quality of genital specimens submitted for the detection of human papillomavirus DNA by consensus PCR. Journal of Clinical Virology, 2004, 29, 127-133.	1.6	5
341	Persistent HPV Infection and Cervical Cancer Risk: Is the Scientific Rationale for Changing the Screening Paradigm Enough?. Journal of the National Cancer Institute, 2010, 102, 1451-1453.	3.0	5
342	Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness?. PLoS ONE, 2013, 8, e67072.	1.1	5

#	Article	IF	CITATIONS
343	Is there a need for a new journal devoted to preventive medicine?. Preventive Medicine Reports, 2014, 1, 1-2.	0.8	5
344	Human papillomavirus variants among Inuit women in northern Quebec, Canada. International Journal of Circumpolar Health, 2015, 74, 29482.	0.5	5
345	Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV): design and methods for a randomised controlled trial. BMJ Open, 2020, 10, e035113.	0.8	5
346	Long-term cervical precancer outcomes after a negative DNA- or RNA-based human papillomavirus test result. American Journal of Obstetrics and Gynecology, 2021, 225, 511.e1-511.e7.	0.7	5
347	Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples. Journal of Medical Virology, 2022, 94, 2824-2832.	2.5	5
348	Human papillomavirusâ€based screening at extended intervals missed fewer cervical precancers than cytology in the <scp>HPV For Cervical</scp> Cancer (<scp>HPV FOCAL</scp>) trial. International Journal of Cancer, 2022, 151, 897-905.	2.3	5
349	Vaccination against human papillomavirus. Cmaj, 2007, 177, 1524-1525.	0.9	4
350	Newlyâ€isolated HPV97, related to HPV18 and 45 is frequently detected in HIVâ€positive men from the montreal area. International Journal of Cancer, 2008, 122, 1195-1197.	2.3	4
351	Effectiveness of Cervical Cancer Screening at Different Ages. Women's Health, 2009, 5, 613-616.	0.7	4
352	Validation of dot blot hybridization and denaturing high performance liquid chromatography as reliable methods for TP53 codon 72 genotyping in molecular epidemiologic studies. BMC Genetics, 2010, 11, 44.	2.7	4
353	Biomarkers of oxidant load and typeâ€specific clearance of prevalent oncogenic human papillomavirus infection: Markers of immune response?. International Journal of Cancer, 2012, 131, 219-228.	2.3	4
354	Preventive Medicine: New Editorial Office but the Same Vision. Preventive Medicine, 2013, 56, 1-2.	1.6	4
355	Cervical human papillomavirus detection is not affected by menstrual phase. Sexually Transmitted Infections, 2013, 89, 202-206.	0.8	4
356	Proving the Causal Role of Human Papillomavirus in Cervical Cancer: A Tale of Multidisciplinary Science., 2020,, 131-147.		4
357	Assessment of the possible inhibitory effect of carrageenan in human papillomavirus DNA testing by polymerase chain reaction amplification. Journal of Medical Virology, 2021, 93, 6408-6411.	2.5	4
358	Epidemiology As a Tool to Reveal Inequalities in Breast Cancer Care. PLoS Medicine, 2006, 3, e48.	3.9	4
359	Association of serum 25-hydroxyvitamin D with prevalence, incidence, and clearance of vaginal HPV infection in young women. Journal of Infectious Diseases, 2021, 224, 492-502.	1.9	4
360	Clinical performance of the BD Onclarity extended genotyping assay for the management of women positive for human papillomavirus in cervical cancer screening. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.1082.2021.	1.1	4

#	Article	IF	Citations
361	Comparative performance of the human papillomavirus test and cytology for primary screening for highâ€grade cervical intraepithelial neoplasia at the population level. International Journal of Cancer, 2022, 150, 1422-1430.	2.3	4
362	Lack of Agreement Between Cervicography and Cytology and the Effect of Human Papillomavirus Infection and Viral Load. Journal of Lower Genital Tract Disease, 2006, 10, 229-237.	0.9	3
363	A New Window into the Natural History of Human Papillomavirus Infection: A View from the ALTS (Atypical Squamous Cells of Undetermined Significance/Lowâ€Grade Squamous Intraepithelial Lesions) Tj ETQq1	l 1 978431∙	43rgBT/Ove
364	Cost-effectiveness analysis: An essential tool to inform public health policy in cervical cancer prevention. Vaccine, 2008, 26, F1-F2.	1.7	3
365	Brief Research Report: Uncertainty-Inducing and Reassuring Facts About HPV: A Descriptive Study of French Canadian Women. Health Care for Women International, 2009, 30, 892-902.	0.6	3
366	Is the UK ready to embrace HPV testing?. Lancet Oncology, The, 2009, 10, 643-644.	5.1	3
367	Radiodiagnostic Imaging in Pregnancy and the Risk of Childhood Malignancy: Raising the Bar. PLoS Medicine, 2010, 7, e1000338.	3.9	3
368	Towards more eclectic evidence-based medicine in cancer prevention and control. Preventive Medicine, 2012, 55, 552-553.	1.6	3
369	Human papillomavirus type 56 polymorphism in Canadian women with and without cervical lesions. Journal of Clinical Virology, 2013, 58, 660-665.	1.6	3
370	Estimates of the future burden of cancer attributable to infections in Canada. Preventive Medicine, 2019, 122, 118-127.	1.6	3
371	Invited Commentary: Rethinking Cervical Cancer Elimination in Terms of Lifetime Risk Rather Than Arbitrarily Defined Age-Standardized Incidence Rates. American Journal of Epidemiology, 2021, 190, 515-518.	1.6	3
372	Is Hodgkin Lymphoma Associated with Hepatitis B and C Viruses? A Systematic Review and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2167-2175.	1.1	3
373	Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial. Contemporary Clinical Trials, 2021, 110, 106560.	0.8	3
374	Cancer Precursors., 2006,, 21-46.		3
375	Temporal variation and identification of factors associated with endogenous retinoic acid isomers in serum from Brazilian women. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 1693-703.	1.1	3
376	A Review of Ethical and Legal Aspects of Gender-Neutral Human Papillomavirus Vaccination. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 919-931.	1.1	3
377	Willingness to Self-Collect a Sample for HPV-Based Cervical Cancer Screening in a Well-Screened Cohort: HPV FOCAL Survey Results. Current Oncology, 2022, 29, 3860-3869.	0.9	3
378	Is Colposcopy Warranted in Women with External Anogenital Warts?. Journal of Lower Genital Tract Disease, 2003, 7, 22-28.	0.9	2

#	Article	IF	CITATIONS
379	Electrofulguration for Low-Grade Squamous Intraepithelial Lesions of the Cervix (CIN 1). Journal of Lower Genital Tract Disease, 2004, 8, 10-15.	0.9	2
380	Perfect is the Enemy of Good: Going to the War on Cancer with Less Evidence than We Could Have. Epidemiologic Methods, 2015 , 4 , .	0.8	2
381	Distribution of Vaccine-Type Human Papillomavirus Does Not Differ by Race or Ethnicity Among Unvaccinated Young Women. Journal of Women's Health, 2016, 25, 1153-1158.	1.5	2
382	Population health intervention research: A renewed commitment to promoting a science of solutions. Preventive Medicine, 2017, 100, 1-2.	1.6	2
383	Persistence of human papillomavirus 16, 18 and 52 variants in Inuit women from Northern Quebec, Canada. International Journal of Circumpolar Health, 2018, 77, 1556556.	0.5	2
384	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. Obstetrical and Gynecological Survey, 2018, 73, 632-634.	0.2	2
385	Prevention of cervical cancer in Latin America: Future challenges and opportunities. Salud Publica De Mexico, 2018, 60, 609.	0.1	2
386	Journal editors as curators of scholarship: A case study in repairing the scientific record. Preventive Medicine, 2018, 110, 114-115.	1.6	2
387	Genetic variants in CYP and GST genes, smoking and risk for head and neck cancers: a gene–environment interaction hospital-based case–control study among Canadian Caucasians. Carcinogenesis, 2019, , .	1.3	2
388	Restoring Dignity in Academic Publishing Is a Collective Duty. JDR Clinical and Translational Research, 2019, 4, 5-8.	1.1	2
389	Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial. Sexually Transmitted Infections, 2021, , sextrans-2021-055009.	0.8	2
390	p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation., 2000, 87, 528.		2
391	Epidemiology of Cervical, Vulvar, and Vaginal Cancers. , 2004, , 3-30.		2
392	Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis. Vaccine, 2022, , .	1.7	2
393	Male Circumcision and Genital Human Papillomavirus (HPV) Infection in Males and Their Female Sexual Partners: Findings From the HPV Infection and Transmission Among Couples Through Heterosexual Activity (HITCH) Cohort Study. Journal of Infectious Diseases, 2022, 226, 1184-1194.	1.9	2
394	Response Design options for the study of second cancers. Journal of Clinical Epidemiology, 1991, 44, 629-632.	2.4	1
395	Human papillomavirus vaccination and screening as the new paradigm in cervical cancer prevention. Therapy: Open Access in Clinical Medicine, 2008, 5, 261-263.	0.2	1
396	Bernard Duval: The Architect of Quebec's HPV Immunization Programme. Public Health Genomics, 2009, 12, 261-263.	0.6	1

#	Article	IF	CITATIONS
397	Managing low grade and borderline cervical abnormalities. BMJ: British Medical Journal, 2009, 339, b3014-b3014.	2.4	1
398	77 PREOPERATIVE DELAYS PRIOR TO RADICAL CYSTECTOMY IN PATIENTS WITH BLADDER CANCER: A POPULATION-BASED STUDY. Journal of Urology, 2013, 189, .	0.2	1
399	Response. Journal of the National Cancer Institute, 2013, 105, 664-665.	3.0	1
400	Sobering realizations in cancer prevention and screening and their lessons. Preventive Medicine, 2015, 76, 129-131.	1.6	1
401	Independent Scientists Provide Guidance for the Future of Cervical Cancer Screening. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 326-327.	0.3	1
402	Lack of Association between Human Papillomavirus Types 6 and 11 Genetic Variants and Cervical Abnormalities: The Ludwig–McGill Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1086-1088.	1.1	1
403	Assessing the time dependence of prognostic values of cytology and human papillomavirus testing in cervical cancer screening. International Journal of Cancer, 2019, 144, 2408-2418.	2.3	1
404	Development and evaluation of a new non-competitive Luminex immunoassay detecting antibodies against human papillomavirus types 6, 11 , 16 and 18 . Journal of General Virology, 2021 , 102 , .	1.3	1
405	Evaluation of the potential promoting effect of 60 Hz magnetic fields on N-ethyl-N-nitrosourea induced neurogenic tumors in female F344 rats. Bioelectromagnetics, 2000, 21, 84.	0.9	1
406	Modeling the Balance of Benefits and Harms of Cervical Cancer Screening with Cytology and Human Papillomavirus Testing. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1436-1446.	1.1	1
407	Efficacy of a Carrageenan Gel in Increasing Clearance of Anal Human Papillomavirus Infections in Men: Interim Analysis of a Double-Blind, Randomized Controlled Trial. Journal of Infectious Diseases, 2023, 227, 402-406.	1.9	1
408	Protection to Self and to One's Sexual Partner After Human Papillomavirus Vaccination: Preliminary Analysis From the Transmission Reduction And Prevention with HPV Vaccination Study. Sexually Transmitted Diseases, 2022, 49, 414-422.	0.8	1
409	Ecological analysis of correlates of cervical cancer morbidity and mortality in Sub-Saharan Africa. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	1
410	Epidemiology of Oncogenic and Nononcogenic HPV Types, and the Evidence for Differences in Their Sexual Transmissibility., 2006,, 20-33.		0
411	BROGLY ET AL. RESPOND. American Journal of Public Health, 2007, 97, 1930-1930.	1.5	0
412	Response to Pretorius and Belinson. Gynecologic Oncology, 2007, 107, 596-597.	0.6	0
413	Reassessing the Epidemiology of Human Papillomavirus Infection: Back to Basics. Sexually Transmitted Diseases, 2008, 35, 283-285.	0.8	О
414	How Multidisciplinary Research Advanced the Mission of Cervical Cancer Prevention. Public Health Genomics, 2009, 12, 264-267.	0.6	0

#	Article	IF	Citations
415	Meeting Report: National Symposium on Infectious Agents and Cancer. Canadian Journal of Infectious Diseases and Medical Microbiology, 2011, 22, e16-e16.	0.7	O
416	Ano-genital human papillomavirus type 97 infection is detected in Canadian men but not women at risk or infected with the human immunodeficiency virus. Virology Journal, 2012, 9, 243.	1.4	0
417	Combatting obesity â€" A helping hand from the business community. Preventive Medicine, 2013, 57, 251-252.	1.6	0
418	Vaccination and Screening in Cervical Cancer Control and Prevention., 2013,, 1175-1189.		0
419	A collaboration between cousins: The Canadian Journal of Public Health and the Canadian Society for Epidemiology and Biostatistics. Canadian Journal of Public Health, 2016, 107, e1-e2.	1.1	0
420	Should we lower the age for routine HPV vaccination in the United States?. Preventive Medicine, 2016, 89, 334-336.	1.6	0
421	Validation of a New HPV Self-Sampling Device for Cervical Cancer Screening: The Cervical and Self-Sample in Screening (CASSIS) Study. Obstetrical and Gynecological Survey, 2018, 73, 461-462.	0.2	0
422	Limitations of simulation models for cervical cancer screening – Authors' reply. Lancet Oncology, The, 2019, 20, e69.	5.1	0
423	Disease detection at the 48â€month exit round of the HPV FOCAL cervical cancer screening trial in women perâ€protocol eligible for routine screening. International Journal of Cancer, 2020, 146, 1810-1818.	2.3	0
424	Reply to: Comments on cumulative risk of cervical intraepithelial neoplasia for women with normal cytology but positive for human papillomavirus: Systematic review and metaâ€analysis. International Journal of Cancer, 2021, 148, 2859-2860.	2.3	0
425	Reply to Feng et al. Journal of Infectious Diseases, 2021, , .	1.9	0
426	Lessons from an unparalleled disruption to cancer prevention and control. Preventive Medicine, 2021, 151, 106686.	1.6	0
427	The noblest among noble public health goals: Preventing suicide. Preventive Medicine, 2021, 152, 106771.	1.6	0
428	Epidemiological methods: a view from the Americas. , 2007, , 275-288.		0
429	Infectious Diseases and Cancer: HPV. Statistics in the Health Sciences, 2009, , 409-429.	0.2	0
430	What makes an eLife paper in epidemiology and global health?. ELife, 2015, 4, .	2.8	0
431	Human Papillomavirus Vaccination: Making Sense of the Public Controversy., 2018,, 59-94.		0
432	The potential harms of personal lubricants. Jornal Brasileiro De Doenças Sexualmente TransmissÃveis, 0, 32, .	0.1	0

#	Article	IF	CITATIONS
433	Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens. Journal of Medical Microbiology, 2020, 69, 960-970.	0.7	0
434	Assessing Epidemiological Relations and the Role of Measurement Errors. , 2002, , 60-74.		O
435	Role of Human Leukocyte Antigen Allele Sharing in Human Papillomavirus Infection Transmission Among Heterosexual Couples: Findings From the Hitch Cohort Study. Journal of Infectious Diseases, 2022, , .	1.9	0